(COO) The Cooper Companies - Ratings and Ratios

The Cooper Companies, Inc. is a global medical device company that operates through two distinct segments: CooperVision and CooperSurgical. CooperVision is a leading manufacturer of contact lenses, offering a diverse range of products that cater to various vision correction needs, including astigmatism, presbyopia, and myopia. The segments products are distributed across the Americas, Europe, the Middle East, Africa, and the Asia Pacific, making it a significant player in the global contact lens market.

CooperSurgical, on the other hand, focuses on womens health and fertility, providing a broad portfolio of products and services, including fertility treatments, medical devices, and contraception solutions. The segments offerings also extend to cryostorage services, such as cord blood and cord tissue storage, which are essential for expectant parents. CooperSurgicals products are sold to healthcare professionals and patients worldwide, establishing the company as a key player in the womens health and fertility market.

From a market perspective, The Cooper Companies, Inc. has demonstrated a strong presence in the healthcare industry, with a market capitalization of $13.65 billion. The companys products are sold through various channels, including distributors, group purchasing organizations, eye care and healthcare professionals, and authorized resellers. With a global footprint and a diverse product portfolio, COO is well-positioned to capitalize on emerging trends in the healthcare industry.

Analyzing the technical data, COOs current price is $71.18, which is below its SMA20 and SMA50 levels, indicating a potential short-term bearish trend. However, the stocks ATR of 2.56 suggests a relatively moderate volatility. Considering the fundamental data, COOs P/E ratio of 32.99 and forward P/E of 17.09 indicate a relatively high valuation, but the companys growth prospects in the contact lens and womens health markets could justify this premium. With a RoE of 5.20, COOs profitability is relatively modest, but the companys strong brand presence and diversified product portfolio are positives.

Forecasting COOs future performance, we can expect the stock to experience a moderate recovery in the short term, driven by the companys strong fundamentals and growth prospects. As the global demand for contact lenses and womens health products continues to rise, COO is well-positioned to capitalize on these trends. Assuming a gradual improvement in the stocks technicals, with the SMA20 and SMA50 levels acting as resistance, we can expect COO to reach $80-$85 in the next 6-12 months, representing a potential upside of 12-20% from current levels.